Madrigal Pharmaceuticals (MDGL) Q3 2026 earnings review
Madrigal turns its first profit, while patient churn stays hidden
Madrigal Pharmaceuticals, the maker of liver disease pill Rezdiffra, earned its first quarterly profit while keeping patient additions steady. Sales jumped 50% from a year ago to $431 million as active patients passed 55,850, and lower marketing spend helped deliver $55 million in net income. Chief executive Bill Sibold also lifted the 2026 growth outlook for the diagnosed US patient pool to more than 30%.
| Rezdiffra net sales | $431.3M +50% from a year ago |
|---|---|
| Active patients on Rezdiffra | >55,850 +6,850 from last quarter by our math |
| Net income | $55.4M net loss of $114.2M a year ago |
| 2026 addressable U.S. market growth outlook | Raised to >30% growth from double-digit growth |
⚖️ Verdict: 🟢 Bullish
The story got better because the company proved its single-drug business can fund its own research and still turn a profit. By our math, quarterly additions reached 6,850 patients and net revenue per patient edged up from the second quarter. One caution: management still withholds how many patients stop taking the pill, and it narrowed the readout for its first cirrhosis trial to late 2027 while adding a second 2,000-patient cirrhosis study.
The question now is whether flat quarterly net additions of about 6,850 patients reflect a booming clinic funnel or a maturing launch. Either new patient starts are climbing fast enough to replace a growing number of drop-offs, or prescriptions are starting to plateau. A disclosure of patient retention rates or fourth-quarter net additions will tell.
🐂 Bull Case
First Quarter of Profit Arrives as Marketing Spend Drops
Madrigal Pharmaceuticals, the maker of liver disease drug Rezdiffra, previously refused to put a date on turning a profit. In the third quarter, the biopharmaceutical company "achieved first quarter of profitability" with $55.4 million in net income, compared with a $57.9 million net loss in the second quarter. Revenue climbed 50.1% from a year ago to $431.3 million, which outpaced operating costs.
- Operating margin: 13.0% of revenue by our math, up from negative 39.6% a year ago
- Selling and administrative costs: 61.6% of revenue, down 11.2 percentage points from a year ago
- Cost of sales: 8.8% of revenue, up 2.5 percentage points from a year ago
Selling and administrative expenses rose 27.1% from a year ago because the company added "headcount for the endocrinology field force expansion that began in the fourth quarter of 2025" and ran consumer ads. Even so, those commercial expenses fell 8.2% from the second quarter. Cost of sales rose on "higher royalties payable to Roche as a result of increased net sales of Rezdiffra in 2026", yet gross margin still improved 2.2 percentage points from the prior quarter to 91.2% by our math.
What to watch: fourth-quarter selling and administrative expenses. Another quarter of flat or falling marketing spend alongside rising sales would show that the commercial team can fund clinical trials without burning cash.
Revenue Per Patient Steps Up alongside Steady Additions
Rezdiffra is an oral pill for metabolic dysfunction-associated steatohepatitis (MASH), a serious fatty liver disease that causes liver scarring. Active patients on the drug reached more than 55,850 at the end of September, up 89.3% from 29,500 a year ago. By our math, Madrigal added 6,850 net patients in the quarter, sitting at the top of the 6,000 to 6,750 range seen over the prior five quarters.
Higher rebates to insurance plans cut net revenue per average patient by 24.8% from a year ago to about $8,227 by our math. However, that per-patient figure rose 3.0% from roughly $7,985 in the second quarter, so sequential revenue growth of 18.4% beat patient growth of 14.0%.
What to watch: net revenue per average patient in the fourth quarter. A stable figure near $8,200 would show that insurance rebates have settled before the calendar resets in January.
Diagnosed Patient Pool Grows Faster Than Planned
Rezdiffra is approved for MASH patients with moderate to advanced liver scarring, known as stages F2 and F3. Chief executive Bill Sibold said the addressable US F2-F3 market is "on track to increase more than 30 percent by year-end 2026". That raises the company's earlier outlook, which called only for double-digit annual market growth.
The US specialist-treated pool reached more than 530,000 patients by June 30, up 15.2% in six months from 460,000 at the end of 2025. Because the diagnosed pool is expanding at this pace, the drug maker can keep adding patients without needing to win a larger share of each doctor's practice.
What to watch: the year-end addressable patient count in the fourth-quarter report. Reaching 598,000 patients, as the 30% target implies by our math, would show that disease awareness campaigns are bringing new patients into clinics.
Positives this quarter didn't test
Two standing positives in Madrigal's commercial and patent story received no new numbers in the third-quarter release, though the company published supporting scientific data.
- Patent protection through 2045: no new patents were announced after three US patents were issued in the second quarter; a new Journal of Hepatology paper showed Rezdiffra works across five common genetic variants, and future quarterly filings will show if any competitors challenge the dosing patents.
- Deeper prescribing within existing doctors' practices: Sibold cited deepening prescriber adoption and 13 real-world abstracts covering nearly 12,000 patients at the upcoming liver conference, but the release gave no scripts-per-doctor figure; the conference call or filing would need to quantify prescriptions per doctor.
🐻 Bear Case
Patient Churn Stays Hidden as Growth Slows
Sibold highlighted deepening adoption as active patients on Rezdiffra passed 55,850 at the end of the third quarter. However, the company reports only the ending patient total each quarter and withholds how many patients started the drug and how many stopped taking it.
That missing breakdown matters because the active patient pool nearly doubled from 29,500 a year ago, while quarterly net additions stayed flat between 6,000 and 6,850 for six straight quarters. Because more patients drop off therapy naturally as the treated pool grows, new patient starts must rise every quarter just to keep net additions near 6,850. Meanwhile, Madrigal again left out the total number of prescribing doctors, a metric it has not updated since reporting more than 10,000 in the third quarter of 2025.
What to watch: any disclosure of gross patient starts or drop-off rates on the conference call. Without those numbers, a sudden plateau in new starts would cause net patient additions to fall without warning.
Cirrhosis Readout Narrows to Late 2027
Madrigal wants to expand Rezdiffra into compensated MASH cirrhosis, an advanced stage of liver scarring called F4c that represents about 245,000 US patients under specialist care. "Our objective in F4c is clear: be first and best," Sibold said. Supporters view the expanding clinical pipeline as a long-term growth driver, but each large study also adds clinical execution risk and financial commitments.
In the third quarter, the drug maker narrowed the expected readout for its pivotal MAESTRO-NASH OUTCOMES trial from 2027 to late 2027. It also announced a second Phase 3 cirrhosis trial, MAESTRO-CSPH, starting in the first half of 2027 "to generate the broadest dataset in F4c and support validation of noninvasive biomarkers for Rezdiffra and future pipeline programs". Enrolling more than 2,000 additional patients with high portal vein blood pressure will add multi-year research costs.
What to watch: the readout window and clinical event accrual for MAESTRO-NASH OUTCOMES in 2027. A slip into 2028 would delay access to the 245,000 cirrhosis patients.
Risks this quarter didn't answer
Four standing concerns around foreign pricing, rival drugs, combination trials, and manufacturing received no update in the earnings release.
- European reimbursement and drug-pricing policy: the release gave no European revenue breakdown or update on most-favoured-nation pricing rules; the quarterly filing's geographic footnote will show if international sales remain minor.
- Competition from weight-loss drugs and oral rivals: the release did not address competing MASH drugs or upcoming rival trial readouts; commentary on the conference call will show how often doctors prescribe Rezdiffra alongside GLP-1 weight-loss drugs.
- Pipeline execution and trial starts: the release did not state whether the planned fourth-quarter drug-interaction study for ervogastat (an experimental oral liver drug licensed from Pfizer) has started; the fourth-quarter update will test that deadline.
- Manufacturing quality: cost of sales fell from $40.0 million in the second quarter to $37.8 million, but the release did not mention the prior quarter's work-in-process inventory write-down; the quarterly filing's inventory footnote will show if any quality risk remains.
💲 Other KPIs
Cash, cash equivalents, restricted cash, and marketable securities rose by $122.9 million, or 14.7%, from $838.9 million at the end of the second quarter by our math. That reverses two quarters of cash declines in the first half of 2026, because Madrigal turned profitable and paid no upfront licensing fees in the quarter.
Research and development spending fell 58.7% from $174.0 million a year ago and dropped 21.3% from $91.2 million in the second quarter. Last year's third quarter included a one-off $117.3 million licensing payment. Year-to-date research spending is $271.7 million by our math, leaving $116.9 million for the fourth quarter under the prior $388.5 million full-year plan.
By our math, dividing $55.4 million of net income by $1.83 of diluted earnings per share points to 30.3 million diluted shares, compared with 29.1 million basic shares at $1.90 per share. Diluted shares rose 3.9% from 29.1 million in the second quarter because turning a profit brought options and warrants into the diluted count.
🔮 Guidance
Raised. Madrigal now expects the addressable US pool of F2-F3 MASH patients under specialist care to grow more than 30% in 2026, up from its earlier plan for double-digit growth. Because the pool grew 15.2% in the first half to 530,000 patients, reaching 30% for the year requires adding at least 68,000 more diagnosed patients in the second half by our math.
Unchanged. The company narrowed the expected readout window for its Phase 3 trial in compensated MASH cirrhosis from 2027 to late 2027. Because the study waits for a set number of clinical liver events to occur before unblinding, the narrower window shows events are accruing at a pace that puts results near the end of next year.
New. Madrigal plans to start a second Phase 3 outcomes study in compensated cirrhosis in the first half of 2027, pending discussions with regulators. The trial will enroll more than 2,000 patients who have clinically significant high blood pressure in the portal vein of the liver.
❓ Key Questions
What are gross patient starts and drop-offs each quarter?
Net patient additions have stayed near 6,000 to 6,850 for six quarters while the active patient pool nearly doubled. Without knowing how many patients stop taking Rezdiffra, investors cannot tell if new starts are speeding up or nearing a ceiling.
How much will the new 2,000-patient cirrhosis trial cost?
Starting MAESTRO-CSPH in the first half of 2027 alongside three planned Phase 2 combination studies will require significant clinical spending. Management has not said how much research expenses will rise in 2027 to fund these trials.
Did the drug-interaction study with ervogastat start on schedule?
Madrigal previously planned to start a drug-interaction trial pairing Rezdiffra with ervogastat in the fourth quarter of 2026 before launching a Phase 2 study in 2027. The third-quarter release did not mention the program.
Is any remaining work-in-process inventory at risk of write-downs?
In the second quarter, Madrigal wrote down $10.4 million of work-in-process inventory that might not meet quality standards, while its remaining work-in-process balance grew. The third-quarter release did not say whether the manufacturing quality issue is resolved.